diethyl sulfosuccinate sodium salt | 7320-45-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: diethyl sulfosuccinate sodium salt
• 英文别名: sodium diethyl sulfosuccinate；1,2-bis-ethoxycarbonyl-ethanesulfonic acid ; sodium-salt；1,2-Bis-aethoxycarbonyl-aethansulfonsaeure; Natrium-Salz；sodium 1,4-diethyl sulfonatosuccinate；Sodium 1,4-diethyl sulphonatosuccinate；sodium;1,4-diethoxy-1,4-dioxobutane-2-sulfonate
• CAS: 7320-45-8
• 化学式: C₈H₁₃O₇S*Na
• 分子量: 276.243
• InChiKey: RIGUOXLGNYMESN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.58
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  118
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  马来酸二乙酯 在 sodium hydrogensulfite 作用下， 以 水 为溶剂， 生成 diethyl sulfosuccinate sodium salt
  参考文献：
  名称：

  琥珀酸盐骨架在 AOT 及其类似分子的无序-有序转变中的作用：通过琥珀酸盐骨架扭转角差异引起的配置的红外吸收光谱检测

  摘要：

  已经详细研究了二烷基磺酸钠（烷基：乙基、正丙基、正丁基、正己基、正庚基、正辛基、正癸基和正十二烷基）和 1,2-双（2-乙基己基）磺基琥珀酸钠（1,2-双（2-乙基己基氧羰基）乙磺酸钠）（AOT ）。结果提供了明确的证据，表明由琥珀酸骨架扭转角的差异引起的两种构型优先稳定在水溶液和固态中，这取决于浓度。因此，该区域的红外光谱可用作阐明 AOT 或其同系物在分子水平上的聚集系统中无序有序转变机制的有力工具。

  DOI：

  10.1246/bcsj.20100002

文献信息

• Raman and IR spectroscopic studies of the interaction between counterion and polar group in self-assembled systems of AOT-homologous “sodium dialkyl sulfosuccinates’'
  作者：Yasuyuki Nagasoe、Naoki Ichiyanagi、Hirofumi Okabayashi、Sandrine Nave、Julian Eastoe、Charmian J. O'Connor

  DOI：10.1039/a904815d

  日期：——

  Headgroup–counterion interactions have been studied for a homologous series of sodium dialkyl sulfosuccinates (SDAS) with propyl, butyl, hexyl, octyl, decyl, undecyl and dodecyl chains as Aerosol-OT analogues. Raman scattering and IR absorption spectra were recorded and compared with those for dimethyl sulfosuccinate monohydrate, diethyl sulfosuccinate trihydrate and diheptyl sulfosuccinate dihydrate, whose crystal structures are known. The spectral features of the C2O and SO3- stretch modes directly reflect the interaction between the polar group and the Na+ ion and depend strongly upon the environment of hydration. The results may be summarized as follows. For the SDAS monohydrates in the solid state, there exists a strong interaction between the β C2O group and the Na+ ion, as a consequence of coordination of the β C2O to the Na+ ion, resulting in splitting of the C2O stretch modes. In particular, the common Raman (IR) bands observed at 1705–1707 (1706–1708) and 1730–1732 (1732–1733) cm-1 may be assigned to the β C2O group coordinated to the Na+ counterion and the hydrated α C2O group, respectively. The extent of splitting of these bands is a measure of the strength of this C2O···Na+ interaction. Coordination of the β C2O to the Na+ ion also affects the C2O deformation modes of the O–C2O linkage. An increased hydration number and longer hydrocarbon chains induce a weak interaction between the C2O group and the Na+ ion. The SO3-···Na+ interaction reflects the SO3- stretch modes, depending upon the extent of hydration. Furthermore, for the SDAS samples in the organic and aqueous microphases, Raman (IR) bands characteristic of the C2O and SO3-1 groups have been used successfully to account for the interaction between the polar group and the Na+ ion.

  头基–对离子相互作用已被研究一系列同系物的硫酸二烷基琥珀酸钠（SDAS），其烷基链包括丙基、丁基、己基、辛基、癸基、十一烷基和十二烷基，作为气溶胶-OT的类似物。记录并比较了拉曼散射和红外吸收光谱，并与已知晶体结构的单水合二甲基琥珀酸、三水合二乙基琥珀酸和二水合二庚基琥珀酸的光谱特征进行了比较。C=O和SO₃⁻的伸缩模式的光谱特征直接反映了极性基团与Na⁺离子之间的相互作用，并且强烈依赖于水合环境。结果可总结如下：在固态的SDAS单水合物中，β C=O基团与Na⁺离子之间存在强相互作用，这是由于β C=O与Na⁺离子的配位，导致C=O伸缩模式的分裂。特别是，在1705–1707 cm⁻¹（1706–1708 cm⁻¹）和1730–1732 cm⁻¹（1732–1733 cm⁻¹）观察到的常见拉曼（红外）特征带可以分别归因于与Na⁺对离子配位的β C=O基团和水合的α C=O基团。这些特征带的分裂程度是C=O· · ·Na⁺相互作用强度的衡量。β C=O与Na⁺离子的配位还影响O–C=O连接的C=O变形模式。增加的水合数和较长的烃链会导致C=O基团与Na⁺离子之间的弱相互作用。SO₃⁻· · ·Na⁺的相互作用反映了SO₃⁻的伸缩模式，依赖于水合程度。此外，对于有机和水相微相中的SDAS样品，C=O和SO₃⁻基团特征的拉曼（红外）特征带已成功用于解释极性基团与Na⁺离子之间的相互作用。
• [EN] PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE MODULATEURS SÉLECTIFS DES RÉCEPTEURS DES ANDROGÈNES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GTX INC

  公开号：WO2013067170A1

  公开（公告）日：2013-05-10

  This invention provides a pharmaceutical composition comprising Compound I-V, including inter alia solid dosage forms of powder-filled capsule formulations, liquid-filled softgel capsules (softgels), tablets, and sustained release dosage forms, and uses thereof in treating a variety of diseases or conditions in a subject, for example, treating a muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.

  这项发明提供了一种包含化合物I-V的药物组合物，包括固体剂型的填粉胶囊制剂、液体填充软胶囊（软胶囊）、片剂和缓释剂型，以及在治疗受试者中各种疾病或症状中的用途，例如治疗肌肉消耗疾病和/或紊乱、骨相关疾病和/或紊乱、代谢综合征、糖尿病及相关疾病等。
• Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
  申请人：Hossainy F.A. Syed

  公开号：US20060147412A1

  公开（公告）日：2006-07-06

  Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a poly(hydroxyalkanoate).

  本发明公开了含有聚羟基烷酸酯的高分子以及用于医疗器械的制剂和制备方法。医疗器械通常包括具有涂层的可植入基质，而涂层含有聚羟基烷酸酯。
• Salts of fenofibric acid and pharmaceutical formulations thereof
  申请人：Cink Drew Russell

  公开号：US20050148594A1

  公开（公告）日：2005-07-07

  In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

  在一个方面，本发明涉及一种分子分散型制剂，其中包括i）芬非布酸，其生理上可接受的盐或衍生物，以及可选的其他活性物质，ii）至少包括一种肠溶性粘合剂的粘合剂组分，以及可选的iii）其他生理上可接受的辅料。在第二个方面，本发明涉及芬非布酸的新盐，与其他芬非布酸盐相比具有光稳定性。
• Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
  申请人：Cink Drew Russell

  公开号：US20080051411A1

  公开（公告）日：2008-02-28

  In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

  在一个方面，本发明涉及一种以分子分散形式的配方，包括i) 芬诺酸、其生理上可接受的盐或衍生物，以及可选的其他活性物质，ii) 至少包括一种肠溶性粘结剂的粘结剂组分，以及可选的iii) 其他生理上可接受的辅料。在第二个方面，本发明涉及芬诺酸的新型盐，与其他芬诺酸盐相比具有光稳定性。